| Identification | Back Directory | [Name]
UNBS-5162 | [CAS]
956590-23-1 | [Synonyms]
CS-1759
UNBS-5162
Uunbs-5162
UNBS-5162, >=98%
UNBS 5162; UNBS-5162
[2-[2-(dimethylamino)ethyl]-1,3-dioxobenzo[de]isoquinolin-5-yl]urea
1-(2-(2-(Dimethylamino)ethyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)urea
Urea, N-[2-[2-(dimethylamino)ethyl]-2,3-dihydro-1,3-dioxo-1H-benz[de]isoquinolin-5-yl]-
1-(2-(2-(dimethylamino)ethyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)urea UNBS-5162 | [Molecular Formula]
C17H18N4O3 | [MDL Number]
MFCD22380608 | [MOL File]
956590-23-1.mol | [Molecular Weight]
326.35 |
| Chemical Properties | Back Directory | [Boiling point ]
526.4±35.0 °C(Predicted) | [density ]
1.389±0.06 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
Soluble in DMSO | [form ]
crystalline solid | [pka]
13.50±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
UNBS5162 is a pan-antagonist of CXCL chemokine expression, with anti-tumor activity. | [Biological Activity]
UNBS5162an amonafide (naphthalimide) derivativeis a potent antitumor agent th at inhibits tumor proliferationprogression and invasiveness. UNBS5162 is a pan-antagonist of CXCL chemokine expression. It appears th at UNBS5162 inhibits melanoma progression through inhibition of the AKT/mTOR signaling pathway. | [in vivo]
UNBS5162 (20 mg/kg, i.v.) increases the therapeutic benefits of taxol in vivo in the orthotopic human PC-3 prostate cancer model[1]. | [IC 50]
CXCL | [storage]
Store at -20°C | [References]
[1] Mijatovic T, et al. UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia. 2008 Jun;10(6):573-86. DOI:10.1593/neo.08290
[2] Tina Mahieu, et al. UNBS5162: A novel naphthalimide derivative with potent pro-autophagic effects in human cancer cells. Cancer Research, 2007 May; 67(9) Supplement.
[3] He D, et al. UNBS5162 inhibits the proliferation of esophageal cancer squamous cells via the PI3K/AKT signaling pathway. Mol Med Rep. 2018 Jan;17(1):549-555. DOI:10.3892/mmr.2017.7893 |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
m.is0513.com/ShowSupplierProductsList15748/0.htm |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|